CTOs on the Move

TruTag Technologies

www.trutags.com

 
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.trutags.com
  • 2045 Lauwiliwili Street Building 3
    Kapolei, HI USA 96707
  • Phone: 808.878.8247

Executives

Name Title Contact Details

Similar Companies

Pharmacy Data Management

Pharmacy Data Management is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus` investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Merchandise

Merchandise Incorporated is a Miamitown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ExonHit Therapeutics

ExonHit Therapeutics is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.